الفهرس 
Pathophysiology of thromboembolic strokeOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
Abstract
Introduction: Ticagrelor is one of the most recent antiplatelet
drugs used to treat ischemic heart disease. Its efficacy
may equal or exceed aspirin in improving clinical outcomes
in patients with acute ischemic stroke who are ineligible for
rt-PA.
Aim of the Work: We aimed at evaluating the safety (as
a primary endpoint) and efficacy (as a secondary endpoint)
of a 180 mg loading dose of ticagrelor given within 9 h from
the onset of first-ever ischemic stroke.
Methods: We conducted
an open-label, randomized prospective controlled
clinical trial between May 2019 and September 2020 on patients
who presented with their first-ever ischemic stroke
and were recruited from the emergency department, of Kafr
el-sheik University Hospitals, Egypt. Eligible patients randomly
received aspirin or ticagrelor loading and maintenance
doses. Treatment began within 9 h of stroke onset.
Results: Aspirin was given to 84 patients; ticagrelor was given
to 85. There was no significant difference between the 2
groups regarding the hemorrhagic and nonhemorrhagic
complications. Patients who received ticagrelor had a better
outcome regarding NIHSS improvement at 2 days and 1week or discharge and a favorable mRS score after 1 week or
discharge and at 90-day follow-up.
Conclusion: Ticagrelor
was noninferior to aspirin regarding safety profile. Compared
with aspirin, ticagrelor had a better clinical outcome
based on NIHSS and mRS in first-ever acute ischemic stroke
patients who received it within 9 h from symptom onset,
leading to a shorter hospital stay.